FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026355284> ?p ?o ?g. }

• W2026355284 abstract "Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has been found to have therapeutic potential for treating cancers associated with impaired DNA repair capabilities, particularly those with deficiencies in the homologous recombination repair (HRR) pathway. Histone deacetylases (HDACs) are important for enabling functional HRR of DNA by regulating the expression of HRR-related genes and promoting the accurate assembly of HRR-directed sub-nuclear foci. Thus, HDAC inhibitors have recently emerged as a therapeutic agent for treating cancer by inhibiting DNA repair. Based on this, HDAC inhibition could be predicted to enhance the anti-tumor effect of PARP inhibitors in cancer cells by blocking the HRR pathway.We determined whether suberoylanilide hydroxamic acid (SAHA), a HDAC inhibitor, could enhance the anti-tumor effects of olaparib on breast cancer cell lines using a cytotoxic assay, cell cycle analysis, and Western blotting. We evaluated how exposure to SAHA affects the expression of HRR-associated genes. The accumulation of DNA double strand breaks (DSBs) induced by combination treatment was assessed. Induction of autophagy was monitored by imaging green fluorescent protein-tagged microtubule-associated protein 1A/1B-light chain 3 (LC3) expression following co-treatment with olaparib and SAHA. These in vitro data were validated in vivo using a human breast cancer xenograft model.Triple-negative breast cancer cell (TNBC) lines showed heterogeneous responses to the PARP and HDAC inhibitors. Co-administration of olaparib and SAHA synergistically inhibited the growth of TNBC cells that expressed functional Phosphatase and tensin homolog (PTEN). This effect was associated with down-regulation of the proliferative signaling pathway, increased apoptotic and autophagic cell death, and accumulation of DNA damage. The combined anti-tumor effect of olaparib and SAHA was also observed in a xenograft model. These data suggest that PTEN expression in TNBC cells can sensitize the cell response to simultaneous inhibition of PARP and HDAC both in vitro and in vivo.Our findings suggest that expression of functional PTEN may serve as a biomarker for selecting TNBC patients that would favorably respond to a combination of olaparib with SAHA. This provides a strong rationale for treating TNBC patients with PTEN expression with a combination therapy consisting of olaparib and SAHA." @default.
• W2026355284 created "2016-06-24" @default.
• W2026355284 creator A5026226793 @default.
• W2026355284 creator A5028906808 @default.
• W2026355284 creator A5042323474 @default.
• W2026355284 creator A5047156899 @default.
• W2026355284 creator A5047219538 @default.
• W2026355284 creator A5058717267 @default.
• W2026355284 creator A5062080961 @default.
• W2026355284 creator A5067977732 @default.
• W2026355284 creator A5070418550 @default.
• W2026355284 creator A5078338048 @default.
• W2026355284 creator A5086634668 @default.
• W2026355284 creator A5088893123 @default.
• W2026355284 date "2015-03-07" @default.
• W2026355284 modified "2023-10-16" @default.
• W2026355284 title "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells" @default.
• W2026355284 cites W1969255865 @default.
• W2026355284 cites W1973268287 @default.
• W2026355284 cites W1973962086 @default.
• W2026355284 cites W1975913714 @default.
• W2026355284 cites W1979562942 @default.
• W2026355284 cites W1980721628 @default.
• W2026355284 cites W1982179592 @default.
• W2026355284 cites W1996931025 @default.
• W2026355284 cites W1997961866 @default.
• W2026355284 cites W2009007206 @default.
• W2026355284 cites W2024940496 @default.
• W2026355284 cites W2035064970 @default.
• W2026355284 cites W2040144233 @default.
• W2026355284 cites W2044570206 @default.
• W2026355284 cites W2050656013 @default.
• W2026355284 cites W2053497568 @default.
• W2026355284 cites W2068751269 @default.
• W2026355284 cites W2073999186 @default.
• W2026355284 cites W2079351077 @default.
• W2026355284 cites W2080251319 @default.
• W2026355284 cites W2082972770 @default.
• W2026355284 cites W2093048712 @default.
• W2026355284 cites W2096439168 @default.
• W2026355284 cites W2100462151 @default.
• W2026355284 cites W2104573784 @default.
• W2026355284 cites W2106196422 @default.
• W2026355284 cites W2110017381 @default.
• W2026355284 cites W2116005493 @default.
• W2026355284 cites W2116012295 @default.
• W2026355284 cites W2116735990 @default.
• W2026355284 cites W2142658272 @default.
• W2026355284 cites W2145121495 @default.
• W2026355284 cites W2151876400 @default.
• W2026355284 cites W2157174734 @default.
• W2026355284 cites W2158794266 @default.
• W2026355284 cites W2162946128 @default.
• W2026355284 cites W2171972386 @default.
• W2026355284 cites W3093265161 @default.
• W2026355284 cites W4254129287 @default.
• W2026355284 doi "https://doi.org/10.1186/s13058-015-0534-y" @default.
• W2026355284 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4425881" @default.
• W2026355284 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25888415" @default.
• W2026355284 hasPublicationYear "2015" @default.
• W2026355284 type Work @default.
• W2026355284 sameAs 2026355284 @default.
• W2026355284 citedByCount "132" @default.
• W2026355284 countsByYear W20263552842015 @default.
• W2026355284 countsByYear W20263552842016 @default.
• W2026355284 countsByYear W20263552842017 @default.
• W2026355284 countsByYear W20263552842018 @default.
• W2026355284 countsByYear W20263552842019 @default.
• W2026355284 countsByYear W20263552842020 @default.
• W2026355284 countsByYear W20263552842021 @default.
• W2026355284 countsByYear W20263552842022 @default.
• W2026355284 countsByYear W20263552842023 @default.
• W2026355284 crossrefType "journal-article" @default.
• W2026355284 hasAuthorship W2026355284A5026226793 @default.
• W2026355284 hasAuthorship W2026355284A5028906808 @default.
• W2026355284 hasAuthorship W2026355284A5042323474 @default.
• W2026355284 hasAuthorship W2026355284A5047156899 @default.
• W2026355284 hasAuthorship W2026355284A5047219538 @default.
• W2026355284 hasAuthorship W2026355284A5058717267 @default.
• W2026355284 hasAuthorship W2026355284A5062080961 @default.
• W2026355284 hasAuthorship W2026355284A5067977732 @default.
• W2026355284 hasAuthorship W2026355284A5070418550 @default.
• W2026355284 hasAuthorship W2026355284A5078338048 @default.
• W2026355284 hasAuthorship W2026355284A5086634668 @default.
• W2026355284 hasAuthorship W2026355284A5088893123 @default.
• W2026355284 hasBestOaLocation W20263552841 @default.
• W2026355284 hasConcept C121608353 @default.
• W2026355284 hasConcept C134935766 @default.
• W2026355284 hasConcept C153911025 @default.
• W2026355284 hasConcept C182979987 @default.
• W2026355284 hasConcept C185592680 @default.
• W2026355284 hasConcept C2776202225 @default.
• W2026355284 hasConcept C2778305200 @default.
• W2026355284 hasConcept C2778502085 @default.
• W2026355284 hasConcept C2779138821 @default.
• W2026355284 hasConcept C2779962180 @default.
• W2026355284 hasConcept C2780110267 @default.
• W2026355284 hasConcept C502942594 @default.
• W2026355284 hasConcept C530470458 @default.
• W2026355284 hasConcept C54355233 @default.

• next